Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-09 pm EDT 		After market 06:07:26 pm
130.2 USD +0.52% Intraday chart for Merck & Co., Inc. 130.3 +0.06%
May. 09 Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma MT
May. 09 Sector Update: Health Care Stocks Steady Pre-Bell Thursday MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma
MT
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
MT
Merck: trial in endometrial cancer fails
CF
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
DJ
Merck's Late-Stage Study for Cancer Drug Keytruda Plus Chemotherapy Fails to Meet Primary Endpoint
MT
Merck: success of 'Merck for Mothers' initiative
CF
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
AQ
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
BU
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents
MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents
MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement
MT
AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement
MT
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
AQ
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
BU
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)
CI
Merck: encouraging results in gastric cancer
CF
Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial
MT
Redburn Atlantic Adjusts Price Target on Merck to $148 From $142
MT
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
BU
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW